Table 1 Clinicopathological characteristics of endometrial cancer patients with computed tomography (CT) at primary diagnosis (nprimary=293) and with CT at follow-up (nfollow−up=152)
From: Abdominal fat distribution in endometrial cancer: from diagnosis to follow-up
nprimary | nfollow−up | p* | |
|---|---|---|---|
Age (years), median [range] | 69 [27, 90] | 70 [27, 90] | 0.14 |
BMI (kg/m2), median [range] | 28 [17, 59] | 28 [17, 57] | 0.22 |
Diabetesa, n (%) | 0.48 | ||
no | 256 (88) | 130 (86) | |
yes | 36 (12) | 21 (14) | |
Menopausal statusa, n (%) | 0.16 | ||
pre/perimenopausal | 24 (8) | 8 (5) | |
postmenopausal | 267 (92) | 143 (95) | |
Preoperative riska, n (%) | < 0.001 | ||
low-risk (EEC grade 1–2) | 175 (62) | 62 (42) | |
high-risk (EEC grade 3/NEEC) | 106 (38) | 85 (58) | |
Primary treatment, n (%) | 0.75 | ||
hysterectomy | 283 (97) | 146 (96) | |
curettage/palliative surgery | 10 (3) | 6 (4) | |
Lymphadenectomy, n (%) | < 0.001 | ||
pelvic | 86 (29) | 47 (31) | |
pelvic and paraaortic | 70 (24) | 53 (35) | |
not performed | 137 (47) | 52 (34) | |
Lymph node metastasisb, n (%) | 0.02 | ||
no | 130 (83) | 78 (78) | |
yes | 26 (17) | 22 (22) | |
Myometrial invasiona, b, n (%) | 0.12 | ||
< 50% | 149 (53) | 70 (48) | |
≥ 50% | 133 (47) | 75 (52) | |
Lymphovascular space invasiona, b, n(%) | 0.07 | ||
no | 215 (80) | 103 (75) | |
yes | 54 (20) | 34 (25) | |
Histological subtype/gradeb, n (%) | < 0.001 | ||
EEC grade 1–2 | 186 (63) | 64 (42) | |
EEC grade 3 | 32 (11) | 26 (17) | |
NEEC | 75 (26) | 62 (41) | |
FIGO stageb, n (%) | < 0.001 | ||
I | 213 (73) | 86 (57) | |
II | 26 (9) | 19 (12) | |
III | 35 (12) | 32 (21) | |
IV | 19 (6) | 15 (10) | |
Additional treatment, n (%) | < 0.001 | ||
no | 169 (58) | 44 (29) | |
chemotherapy | 113 (39) | 102 (67) | |
radiotherapy | 4 (1) | 4 (2) | |
chemoradiotherapy | 3 (1) | 1 (1) | |
hormonal treatment | 2 (1) | 1 (1) | |
other | 2 (1) | - | |
Progressing or recurrent disease | < 0.001 | ||
no | 227 (77) | 99 (65) | |
yes | 66 (23) | 53 (35) |